Common questions about Mirtastad (FAQ)
Q: Is Mirtastad a controlled substance?
According to official information, Mirtastad (mirtazapine) is not classified as a controlled substance by regulatory agencies such as the U.S. Drug Enforcement Administration (DEA).
Q: How long does Mirtastad take to start working for its main purpose?
Studies and official information indicate that patients may observe an improvement in depressive symptoms as early as one to two weeks after beginning therapy. However, as with many medications of this kind, the full documented benefit may take several weeks to be observed.
Q: What should I do if I miss a dose of Mirtastad?
Official administration instructions specify that if a dose is missed, regulatory guidance generally advises against taking a double or extra dose. Resuming the typical schedule with the next scheduled dose is the expected procedure.
Q: Is Mirtastad known to interact with birth control pills?
Official drug interaction data indicates that components often found in oral contraceptives, such as ethinyl estradiol, may cause a slight increase in the blood level of mirtazapine. This means a potential for an increased concentration of Mirtastad in the body is documented, which may increase the likelihood of side effects.
Q: Is Mirtastad known to cause sexual side effects?
Some sexual adverse reactions, such as painful or prolonged erection, have been reported in safety documents, although the incidence is not consistently documented as a common event. Official prescribing information should be consulted for a complete list of reported side effects.
Q: How long does Mirtastad stay in your system after stopping?
The mean elimination half-life of mirtazapine in adults is typically estimated to be between 20 and 40 hours. The half-life is the time it takes for half of the drug to be cleared from the system.
Q: Can Mirtastad affect blood pressure levels?
Yes, official prescribing information notes that Mirtastad can sometimes cause orthostatic hypotension. This is a drop in blood pressure that can occur when standing up from a sitting or lying position, which can lead to dizziness or lightheadedness.
Q: What do official sources say about the potential for addiction with Mirtastad?
Official drug labeling indicates a low potential for abuse or dependence. The need to reduce the dose gradually when discontinuing is a measure to prevent symptoms associated with abrupt cessation.
Q: What is the general success rate described in clinical studies for Mirtastad?
Clinical studies used to evaluate the medicine's effectiveness for Major Depressive Disorder (MDD) define success by measuring patient 'response,' often set as a 50% or greater decrease in depressive symptoms. Official studies note that a measurable percentage of patients reached this response benchmark in trials, exceeding the rate observed in those who received a placebo.
Q: Is there a generic version of Mirtastad available?
Yes, the original brand name product is available, but regulatory agencies have also approved multiple generic versions of the mirtazapine tablet. Generic versions contain the same active ingredient and are required to meet the same standards for quality and effectiveness as the brand-name product.
Q: What is the difference between Mirtastad and its parent class of drugs?
Mirtastad (mirtazapine) is chemically classified as belonging to the tetracyclic antidepressant class. However, it is pharmacologically known as a Noradrenergic and Specific Serotonergic Antagonist (NaSSA). This second designation highlights its unique way of working by blocking specific receptors to increase the release of serotonin and norepinephrine, distinguishing it from the older tetracyclics.
